GlassScriptPhysician profile
Carlton Edwin Miller
NPI 1295793727
$12,010.66
in general payments reported to CMS, 2019-2025
42 companies · $2,166 in 2025
The $2,166 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $1,069 · 2021: $2,017 · 2022: $1,583 · 2023: $1,926 · 2024: $2,192 · 2025: $2,166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,209 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,209.28 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,503.08 | 2019-2025 | Enbrel, Tavneos, Krystexxa |
| Janssen Biotech, INC. | $1,774.31 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Abbvie INC. | $1,026.04 | 2019-2025 | |
| Pfizer INC. | $992.93 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $672.17 | 2020-2025 | Acthar |
| Ucb, INC. | $658.96 | 2021-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $427.06 | 2019-2025 | |
| Horizon Therapeutics Plc | $361.05 | 2020-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $356.78 | 2019-2025 | Orencia |
| Lilly USA, LLC | $330.92 | 2019-2024 | Taltz |
| Radius Health, INC. | $288.63 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $275.00 | 2019-2025 | Benlysta |
| Ani Pharmaceuticals, INC. | $191.19 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $190.47 | 2021-2025 | Saphnelo |
| Bioventus LLC | $179.26 | 2019-2025 | Durolane, Durolane, Xcell |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $169.73 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.73 | 2020-2024 | Ofev, Spevigo, Cyltezo |
| Aurinia Pharma U.S., INC. | $162.01 | 2021-2025 | Lupkynis |
| Organon LLC | $147.39 | 2024-2025 | Hadlima, Renflexis, Nexplanon |
| Alexion Pharmaceuticals, INC. | $131.46 | 2022-2025 | Strensiq |
| Actelion Pharmaceuticals US, INC. | $125.71 | 2020-2024 | Opsumit, Uptravi |
| Sandoz INC. | $119.16 | 2023-2024 | Hyrimoz |
| Genzyme Corporation | $98.13 | 2020-2024 | |
| Janssen Scientific Affairs, LLC | $95.47 | 2022 | |
| Genentech USA, INC. | $70.46 | 2019-2024 | Actemra |
| Fidia Pharma USA INC. | $66.83 | 2019 | |
| Octapharma USA, INC. | $45.61 | 2022-2023 | Octagam Immune Globulin (Human) |
| Regeneron Healthcare Solutions, INC. | $42.92 | 2019 | |
| Biocon Biologics INC | $37.17 | 2023-2024 | Hulio |
| Fresenius Kabi USA, LLC | $36.60 | 2023-2025 | Idacio |
| Mylan Institutional INC. | $34.59 | 2023 | Hulio |
| Pacira Therapeutics, INC. | $29.98 | 2019 | |
| Sobi, INC | $29.29 | 2019-2023 | |
| Medexus Pharma, INC. | $28.13 | 2019 | |
| Invivyd INC | $25.81 | 2025 | Pemgarda |
| Ferring Pharmaceuticals INC. | $23.92 | 2025 | Euflexxa |
| Kiniksa Pharmaceuticals International, Plc | $21.68 | 2024 | Arcalyst |
| Tonix Medicines, INC. | $17.80 | 2025 | Tonmya |
| Pharming Healthcare, INC. | $17.27 | 2023 | Ruconest |
| Ultragenyx Pharmaceutical INC. | $17.04 | 2021 | |
| Hikma Pharmaceuticals USA | $11.96 | 2019 | |
| Sebela Pharmaceuticals INC. | $11.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlton Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.